CureVac fails in pivotal trial; Japan plans to lift Tokyo’s virus emergency on 20 June, one month before games
- Double-jabbed UK tourists could skip amber-list quarantine
- France and Spain to ease mask-wearing as vaccine schemes gather pace
- Ryanair and airport group launch legal action over ‘traffic light’ system
- See all our coronavirus coverage
German biotech CureVac NV said on Wednesday its Covid-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union, Reuters reports.
The disappointing efficacy of the shot known as CVnCoV emerged from an interim analysis based on 134 Covid-19 cases in the study with about 40,000 volunteers in Europe and Latin America.
The stakes for CureVac and prospective buyers of its vaccine in Europe had risen after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.
CureVac’s shot was also expected to help in low and middle-income countries that have lagged far behind richer nations in the global immunisation drive.
As CureVac’s only major supply deals, the European Union in November secured up to 405 million doses of the vaccine, of which 180 million are optional. That was followed by a memorandum of understanding with Germany for another 20 million doses.
CureVac’s US traded shares fell 50.6% to $46.81 in after-hours trading following publication of the data.
Hello and welcome to today’s live coverage of the coronavirus pandemic.
Japan plans to lift Tokyo’s virus emergency on June 20, a month before the Olympics, the government announced Thursday as reports said only 10,000 spectators would be allowed at Games events.
